补肾强骨方对原发性骨质疏松症患者血清TRACP5b表达的影响
Effect of Bushen Qianggu Fang on serum TRACP5b expression in patients with primary osteoporosis
刘磊 1周健1
作者信息
- 1. 丽水市中医院 骨伤科,浙江 丽水 323000
- 折叠
摘要
目的 探讨补肾强骨方对原发性骨质疏松症患者血清TRACP5b表达的影响.方法 选取2017年1月~2017年7月丽水市中医院收治的60例原发骨质疏松患者,按照采用随机数字表法分为治疗组与对照组,治疗组口服钙尔奇D片+补肾强骨方治疗,对照组口服钙尔奇D片+福善美片,疗程3个月.观察比较2组患者的中医症状评分,骨密度,疼痛评分,骨折风险量表评估和实验室检查指标.结果 ①治疗3个月,治疗组较对照组症状明显改善(P<0.05);②随访3个月,治疗组骨密度测定较对照组显著改善(P<0.05);③治疗2个月、3个月后,治疗组疼痛评分、骨折风险评估、血清TRACP5b较对照组均显著改善(P<0.05).结论 补肾强骨方能有效缓解原发性骨质疏松症患者的临床症状,降低骨质疏松性骨折的风险.
Abstract
Objective To investigate the effect of Bushen Qianggu Fang on serum TRACP5b expression in patients with primary osteoporosis. Methods A total of 60 patients with primary osteoporosis were selected from January 2015 to July 2017. The patients were divided into two groups: the treatment group and the control group. The treatment group was treated with oral Calcium D tablet + Bushen Qianggu fang treatment. The control group was treated with oral Erqi D film and Fu Shanmei tablet for 3 months. TCM symptom score, bone mineral density, pain score, fracture risk assessment, TRACP5b. Results ①After 3 months of treatment, the symptoms in the treatment group were significantly improved compared with the control group (P<0.05). ② Followed up for 6 months,the bone mineral density of the treatment group was significantly improved compared with the control group (P<0.05). After 2 months and 3 months, the pain score and the risk assessment of the treatment group and the serum TRACP5b in the treatment group were significantly improved compared with the control group (P<0.05) .Conclusion Bushen Qiangguang Fang can effectively relieve the clinical symptoms of patients, Inhibit excessive bone turnover, so that bone metabolism to achieve a new balance, improve bone mass.
关键词
补肾强骨方/原发性骨质疏松症/抗酒石酸酸性磷酸酶5bKey words
Bushen Qianggu fang/primary osteoporosis/tartrate-resistant acid phosphatase 5 b引用本文复制引用
基金项目
2016年丽水市科技计划项目(2016GYX47)
出版年
2017
NETL
NSTL
维普
万方数据